European Journal of Gastroenterology & Hepatology最新文献

{"title":"Atrial fibrillation in patients with alcohol-associated hepatitis leads to increased mortality.","authors":"Harshavardhan Sanekommu, Sowmya Dandu, Sneha K Jayaswal, Mahmut C Ozkan, Vera Hapshy, Christopher Schreiber, Talal Khurshid Bhatti, Farah Deshmukh, Don C Rockey","doi":"10.1097/MEG.0000000000003223","DOIUrl":"10.1097/MEG.0000000000003223","url":null,"abstract":"<p><strong>Background: </strong>Alcohol consumption is associated with increased risk for development of atrial fibrillation. Outcomes of patients with atrial fibrillation in the context of acute alcohol-associated hepatitis have yet to be investigated.</p><p><strong>Methods: </strong>We performed a retrospective study of patients with alcohol-associated hepatitis from the National Inpatient Sample (2016-2019), comparing those with and without concurrent atrial fibrillation. Subgroup analysis with and without cirrhosis was alone performed. Statistical analysis performed using STATA 16.1 and multivariate logistic and linear regression.</p><p><strong>Results: </strong>Among 475 600 patients with alcohol-associated hepatitis, 27 675 (5.8%) had atrial fibrillation. Patients with atrial fibrillation had a nearly two-fold increased in-hospital mortality (6.9%) compared with those without atrial fibrillation (3.9%) [adjusted odds ratio (OR) = 1.35, 95% confidence interval (CI) = 1.20-1.53] and higher odds of developing acute kidney injury (OR = 1.23, 95% CI = 1.15-1.32). They also had longer hospital stays and higher total hospital charges (7.5 vs. 6.0 days and $20 005 vs. $14 714, respectively). Among patients with alcohol-associated hepatitis and atrial fibrillation, 33% also had cirrhosis (n = 9190), and these patients had an even higher mortality rate (11.3%) than those with alcohol-associated hepatitis and atrial fibrillation alone (4.7%). Acute coronary syndrome, chronic kidney disease, and obesity were independently associated with increased mortality.</p><p><strong>Conclusion: </strong>Patients with alcohol-associated hepatitis who have atrial fibrillation have an increased risk of in-hospital mortality and underlying cirrhosis compounds this risk. Early recognition of the effect of concomitant atrial fibrillation and alcohol-associated hepatitis could provide an opportunity for intervention.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":"38 8","pages":"971-976"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"'Presence of alarm symptoms at coeliac disease diagnosis is not associated with poorer long-term treatment outcomes' [Letter].","authors":"Jingfeng Zhou","doi":"10.1097/MEG.0000000000003205","DOIUrl":"10.1097/MEG.0000000000003205","url":null,"abstract":"","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":"38 8","pages":"986"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rectal indomethacin alone versus combined with prophylactic pancreatic duct stenting for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a systematic review and meta-analysis.","authors":"Luis E Cueva-Cañola, Karoly P Zuñiga-Montaño, Andrea C Beltran-De la Fuente, Wilmer E Díaz-Gutierrez, Oscar Eduardo Camacho-Hernández, Yverong Gu","doi":"10.1097/MEG.0000000000003261","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003261","url":null,"abstract":"<p><strong>Background: </strong>Postendoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most frequent complication of ERCP, particularly in high-risk patients. Although rectal indomethacin and prophylactic pancreatic duct stenting (PDS) independently reduce PEP risk, the incremental benefit of combining both strategies remains uncertain. This meta-analysis evaluates the effectiveness of rectal indomethacin alone versus indomethacin plus prophylactic PDS for PEP prevention in high-risk patients.</p><p><strong>Methods: </strong>PubMed, Embase, Ovid/MEDLINE, and the Cochrane Library were searched from inception through 28 January 2026. Randomized controlled trials (RCTs) and cohort studies comparing rectal indomethacin alone with indomethacin plus prophylactic PDS in high-risk ERCP patients were included. Risk ratios with 95% confidence intervals (CI) were pooled using a random-effects model. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation framework.</p><p><strong>Results: </strong>Six studies (three RCTs and three cohort studies) including 3753 patients were analyzed. Overall, PEP occurred less frequently with combination prophylaxis than with indomethacin alone (risk ratio = 0·73, 95% CI: 0·60-0·89, I2 = 9%). Reductions were also observed for mild PEP (risk ratio = 0·73, 95% CI: 0·58-0·93, I2 = 0%) and moderate-to-severe PEP (risk ratio = 0·73, 95% CI: 0·55-0·98, I2 = 0%). The protective effect on overall PEP was confirmed in analyses restricted to RCTs. Based on randomized evidence, the certainty of the evidence was moderate.</p><p><strong>Conclusion: </strong>In high-risk ERCP patients, adding prophylactic PDS to rectal indomethacin was associated with a reduced incidence of PEP compared with indomethacin alone.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of surgical risk in Crohn's disease: impact of the biologic therapy era on time to first surgery in a Bosnian tertiary referral center.","authors":"Amar Habibović, Naid Dizdarević, Emir Tulumović, Nedim Selimović, Mirela Bašić Denjagić, Zlatan Mehmedović, Nevena Poljašević Rahmanović, Nermin Salkić","doi":"10.1097/MEG.0000000000003257","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003257","url":null,"abstract":"<p><strong>Objective: </strong>Contemporary surgical risk data from Southeastern Europe are limited. We assessed cumulative surgical probabilities, independent predictors of surgery, and the impact of evolving therapeutic strategies in a Bosnian tertiary referral cohort.</p><p><strong>Methods: </strong>This retrospective cohort study included 153 patients with Crohn's disease treated at University Clinical Center Tuzla between 2009 and 2023. Calendar-period analysis estimated contemporary surgical risk, while natural-history analysis characterized progression from diagnosis. Sequential multivariable Weibull regression identified independent predictors of time to first surgery.</p><p><strong>Results: </strong>Cumulative probabilities of surgery at 1, 5, and 10 years were 3, 11, and 34%, respectively. Five factors independently reduced surgical risk. Early biologic therapy showed the largest effect (hazard ratio: 0.22, 95% confidence interval: 0.07-0.73; P = 0.014), followed by colonic location (hazard ratio: 0.37, 95% confidence interval: 0.16-0.81; P = 0.014), inflammatory phenotype (hazard ratio: 0.53, 95% confidence interval: 0.32-0.85; P = 0.011), diagnosis during the biologic era (≥2017; hazard ratio: 0.56, 95% confidence interval: 0.35-0.88; P = 0.013), and early azathioprine initiation (hazard ratio: 0.61, 95% confidence interval: 0.40-0.93; P = 0.022). Sequential modeling confirmed additive protective effects of therapeutic exposures. Early surgery was associated with lower subsequent biologic use than no early surgery (27.5 vs. 81.4%; P < 0.001).</p><p><strong>Conclusion: </strong>Surgical risk in this Southeastern European cohort aligns with Western estimates. Colonic location and inflammatory phenotype were intrinsic protective factors, whereas early azathioprine, early biologic therapy, and biologic-era diagnosis independently reduced surgical risk. These findings support early combined therapy for high-risk patients.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148879847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal and urological complications in patients with inflammatory bowel disease.","authors":"Georgios Psarakis, Ioannis Drygiannakis, Kalliopi Foteinogiannopoulou, Eleni Orfanoudaki, Konstantinos Karmiris, Anna-Bettina Haidich, Ioannis E Koutroubakis","doi":"10.1097/MEG.0000000000003249","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003249","url":null,"abstract":"<p><strong>Objective: </strong>Renal and urological manifestations are understudied extraintestinal features of inflammatory bowel disease (IBD). Our aim was to estimate their prevalence and identify associated clinical parameters.</p><p><strong>Methods: </strong>This retrospective, single-center, observational study, included IBD patients with at least 1 year of follow-up and documented renal function monitoring. Demographic, clinical, and laboratory data were collected. The primary outcome was renal injury defined as acute kidney injury (AKI), chronic kidney disease (CKD), or both during follow-up. Secondary outcomes were AKI, CKD, and urolithiasis. Associations were assessed using univariate and multivariable logistic regression analyses.</p><p><strong>Results: </strong>A total of 660 patients were included [379 (57.4%) male; 368 (56%) had Crohn's disease and 292 (44%) ulcerative colitis]. The primary outcome occurred in 54 patients (8.2%), AKI in 23 (3.5%), CKD in 35 (5.3%), and urolithiasis in 48 (7.3%). Independent risk factors for renal injury included IBD-related surgery [adjusted odds ratio (aOR): 2.69, 95% confidence interval (CI): 1.25-5.80, P = 0.012], extensive ulcerative colitis (aOR: 2.81, 95% CI: 1.11-7.73, P = 0.035), arterial hypertension (aOR: 2.43, 95% CI: 1.20-4.94, P = 0.014), male sex, and Charlson Comorbidity Index. AKI was associated with older age at IBD diagnosis and a higher frequency of disease flares. In a multivariable model, IBD-related surgery was independently associated with urolithiasis (aOR: 2.20, 95% CI: 1.03-4.70, P = 0.042).</p><p><strong>Conclusion: </strong>Renal and urological complications are relatively common in IBD. IBD-related surgery, extensive ulcerative colitis, and cardiometabolic comorbidities are associated with renal injury, while IBD-related surgery is also independently associated with urolithiasis.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148561141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferric carboxymaltose for iron-deficiency anemia secondary to gastrointestinal bleeding: a systematic review and meta-analysis.","authors":"Yuqing Yang, Huiting Hou, Jing Wu, Liu Han, Deliang Liu, Xiaojun Li, Yuyong Tan","doi":"10.1097/MEG.0000000000003251","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003251","url":null,"abstract":"<p><p>This systematic review and meta-analysis assessed the efficacy and safety of ferric carboxymaltose (FCM) in treating iron-deficiency anemia secondary to gastrointestinal bleeding. A comprehensive search across multiple databases identified randomized controlled trials comparing FCM with other iron formulations. A total of 13 publications, reporting 16 trials and involving 1939 patients, were included. Pooled analyses demonstrated that FCM led to significantly greater improvements in key anemia parameters compared to alternative iron therapies, including a higher hemoglobin response rate [risk ratio = 1.24, 95% confidence interval (CI): 1.14-1.34], increased serum ferritin levels (mean difference = 293.52, 95% CI: 168.76-418.27), and greater transferrin saturation (mean difference = 9.71, 95% CI: 5.19-14.22). The overall incidence of drug-related adverse events was comparable between groups (risk ratio = 0.82, 95% CI: 0.51-1.34); however, FCM was associated with a substantially increased risk of hypophosphatemia (risk ratio = 21.00, 95% CI: 8.90-49.56). Notably, subgroup analysis confirmed that this therapeutic advantage remained consistent across both acute and chronic gastrointestinal bleeding settings. In conclusion, FCM is effective in correcting anemia in patients with gastrointestinal bleeding-related iron deficiency, despite a well documented risk of hypophosphatemia. Further research is warranted to optimize dosing strategies and identify patient subgroups most likely to benefit from FCM therapy.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148561173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of a prediction score for identifying a mild course of Crohn's disease.","authors":"Diogo Couto Sousa, Samuel Raimundo Fernandes, André Da Silva Neves, Filipa Pereira, Sérgio Bronze, Inês Coelho Rodrigues, Sofia Saraiva, Ana Rita Gonçalves, Ana Valente, Luís Correia","doi":"10.1097/MEG.0000000000003242","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003242","url":null,"abstract":"<p><strong>Introduction: </strong>Crohn's disease has a heterogeneous course. Early identification of patients likely to follow a mild trajectory remains challenging. The prediction score for a mild course of Crohn's disease (PreMiCC) was recently proposed, but external validation is lacking.</p><p><strong>Methods: </strong>This single-center retrospective study included patients diagnosed with Crohn's disease between 2004 and 2024. The PreMiCC score was calculated at diagnosis using the original variables: age, C-reactive protein, perianal disease, endoscopic severity, and complications. Patients were classified as having a score ≤2 or >2. Outcomes included mild disease course, need for biologic therapy, Crohn's disease-related surgery or hospitalization, and time to treatment escalation.</p><p><strong>Results: </strong>A total of 342 patients (51% male; mean age 35 ± 16 years) were included, with a mean follow-up of 9 ± 5 years. At diagnosis, 55% had a PreMiCC score ≤2. A mild disease course occurred in 31% of patients and was more common in those with a score ≤2 than >2 (42% vs. 17%; P < 0.001). Patients with a score >2 more frequently required biologic therapy (80% vs. 54%; P < 0.001) and hospitalization (15% vs. 7%; P = 0.023), whereas the need for surgery did not differ between groups (20% vs. 17%; P = 0.415). The PreMiCC score independently predicted biologic therapy [odds ratio = 1.65, 95% confidence interval (CI) = 1.33-2.04; P < 0.001]. Time to treatment escalation was shorter in patients with a score >2 (log-rank P < 0.001). The model showed acceptable discrimination (area under the receiver operating characteristic curve = 0.708, 95% CI = 0.649-0.768), with 74% sensitivity, 55% specificity, 42% positive predictive value, and 83% negative predictive value.</p><p><strong>Conclusion: </strong>This first external validation confirms the predictive value of the PreMiCC score in a real-world cohort, supporting its use as a simple tool for early risk stratification in Crohn's disease.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148561217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of tofacitinib as rescue therapy in biological-naive patients with steroid-refractory acute severe ulcerative colitis: a multicentric retrospective analysis.","authors":"Suprabhat Giri, Kayal Vizhi, Sumaswi Angadi, Shivaraj Afzalpurkar, Gaurav Khatana, Sunil Kasturi, Bhavik Shah, Zubin Dev Sharma, Bimal Kumar Sahu, Jijo Varghese, Anuraag Jena, Akshay Kulkarni, Naresh Bhat, Sukanya Bhrugumalla, Sandesh Kolaserry, Girish Kumar Pati, Preetam Nath, Manoj Kumar Sahu, Anil Chandra Anand","doi":"10.1097/MEG.0000000000003254","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003254","url":null,"abstract":"<p><strong>Objectives: </strong>Tofacitinib, a Janus kinase inhibitor approved for moderate-to-severe ulcerative colitis, has limited data in acute severe ulcerative colitis (ASUC), particularly in biologic-naive patients. This study evaluated its safety and efficacy as second-line therapy after intravenous steroid failure.</p><p><strong>Materials and methods: </strong>The present study retrospectively evaluated patients with biological-naive, steroid-refractory ASUC from 11 tertiary care centers in India who received tofacitinib from January 2022 to June 2024. Clinical response [≥3-point and ≥30% partial Mayo score (PMS) reduction with ≥1-point rectal bleeding decrease] was assessed on days 7 and 10; clinical and steroid-free remission (PMS 0-1, with or without steroids) were assessed at weeks 8 and 24.</p><p><strong>Results: </strong>The present study recruited 52 biologic-naive patients (61.5% male, median age: 35 years) with steroid-refractory ASUC who were initiated on tofacitinib. A response to tofacitinib was observed within 1 week of therapy in 73.1% (38/52) of patients, while 90.4% (47/52) had a response within 10 days of therapy. At 8 and 24 weeks, 71.1% (37/52) and 67.3% (35/52) were in clinical remission, and 65.4% (34/52) and 61.5% (32/52) were in steroid-free clinical remission, respectively. Adverse events were reported in 17.3% (9/52) of cases, of which four required temporary (tuberculosis: 2, herpes zoster: 2) and one permanent drug discontinuation (herpes zoster: 1).</p><p><strong>Conclusion: </strong>Tofacitinib is a promising second-line therapy for ASUC patients after the failure of steroid therapy, with greater than 60% of patients having steroid-free clinical remission at the 24th week of therapy. Further randomized trials are needed to validate the study's findings.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148561211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contribution of the sphincter of O'Beirne in the pathophysiology of slow transit constipation as shown by low resolution manometry.","authors":"Gabrio Bassotti, Roberto Cirocchi, Sara Bologna, Edda Battaglia, Ji-Hong Chen, Jan D Huizinga","doi":"10.1097/MEG.0000000000003250","DOIUrl":"10.1097/MEG.0000000000003250","url":null,"abstract":"<p><strong>Background: </strong>Key features of the pathophysiology of slow transit constipation are known. Colonic motility is markedly reduced, related to increased sympathetic activity, and retrograde propulsive activity is present, originating from the rectosigmoid junction (the sphincter of O'Beirne) and rectum. Furthermore, the sphincter of O'Beirne does not persistently relax when propulsive motor activity descends upon it, creating a barrier for stool transit into the rectum.</p><p><strong>Methods: </strong>Our aim was to assess whether low-resolution manometry can provide information on the role of the sphincter of O'Beirne in patients with chronic slow transit constipation. To this end, we analyzed archival 24-h colonic manometric tracings from patients with slow transit constipation to assess the presence and characteristics of the sphincter of O'Beirne.</p><p><strong>Results: </strong>Reliable tracings were obtained from 23 patients with a confirmed recording port at the sphincter location. Although colonic activity was significantly reduced to about 3% of normal, the activity of the sphincter of O'Beirne showed normal activity, with 10% of the activity comprised of the 3 cycles/min cyclic motor activity.</p><p><strong>Conclusion: </strong>In conclusion, the sphincter of O'Beirne is not dysfunctional in chronic constipation; however, because of its continued presence and the lack of propulsive activity that relaxes the sphincter through a functional colo-anal reflex, it contributes to the symptoms of constipation.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microscopic gastritis and colitis: two tales of the same world.","authors":"Vincenzo Villanacci, Lucrezia Laschi, Giovanni Latella, Celia Escudero-Hernández, Gabrio Bassotti","doi":"10.1097/MEG.0000000000003199","DOIUrl":"https://doi.org/10.1097/MEG.0000000000003199","url":null,"abstract":"","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":"38 7","pages":"881-883"},"PeriodicalIF":1.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148053498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}